Invitae (Invitae) Debt-to-Equity

: -1.39 (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

Invitae's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $48.5 Mil. Invitae's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $1,459.9 Mil. Invitae's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-1,083.4 Mil. Invitae's debt to equity for the quarter that ended in Sep. 2023 was -1.39.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Invitae's Debt-to-Equity or its related term are showing as below:

NVTAQ' s Debt-to-Equity Range Over the Past 10 Years
Min: -44.19 Med: 0.37 Max: 17.19
Current: -1.39

During the past 11 years, the highest Debt-to-Equity Ratio of Invitae was 17.19. The lowest was -44.19. And the median was 0.37.

NVTAQ's Debt-to-Equity is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 0.24 vs NVTAQ: -1.39

Invitae Debt-to-Equity Historical Data

The historical data trend for Invitae's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invitae Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.48

0.84

0.23

0.58

17.19

Invitae Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial															11.03	17.19	-44.19	-7.88	-1.39

Competitive Comparison

For the Diagnostics & Research subindustry, Invitae's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invitae Debt-to-Equity Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Invitae's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Invitae's Debt-to-Equity falls into.

Invitae Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Invitae's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(19.721	+	1731.282)	/	101.836
	=	17.19

Invitae's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(48.505	+	1459.874)	/	-1083.404
	=	-1.39

Invitae (OTCPK:NVTAQ) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Invitae Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Invitae's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Invitae (Invitae) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Invitae Corp (OTCPK:NVTAQ) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

NVTA:Mexico IV8:Germany

Address

1400 16th Street, San Francisco, CA, USA, 94103

Website

https://www.invitae.com

Invitae Corp operates as a genetic information company in diagnostic and research industry. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders and other hereditary conditions.

Executives

Ana J. Schrank	officer: Chief Financial Officer	1400 16TH STREET, SAN FRANCISCO CA 94103
Robert M. Guigley	officer: Chief Commercial Officer	1400 16TH STREET, SAN FRANCISCO CA 94103
Robert Iv Dickey	officer: See Remarks	320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Jeff Parsons	officer: See remarks	2575 AUGUSTINE DRIVE, SANTA CLARA CA 95054
Robert L Nussbaum	officer: Chief Medical Officer	458 BRANNAN STREET, SAN FRANCISCO CA 94107
Thomas Brida	officer: General Counsel	458 BRANNAN STREET, SAN FRANCISCO CA 94107
Robert F. Werner	officer: Chief Accounting Officer	2500 FABER PLACE, PALO ALTO CA 94303
Yafei Wen	officer: Chief Financial Officer	1400 16TH STREET, SAN FRANCISCO CA 94103
Kenneth D. Knight	officer: Chief Operating Officer	1400 16TH STREET, SAN FRANCISCO CA 94103
William H Osborne	director	1415 WEST 22ND STREET, SUITE 1100, OAK BROOK IL 60523
Sean E George	director, officer: CEO	458 BRANNAN STREET, SAN FRANCISCO CA 94107
Shelly D Guyer	officer: Chief Financial Officer	1025 GREEN STREET, SAN FRANCISCO CA 94133
Katherine Stueland	officer: Chief Commercial Officer	458 BRANNAN STREET, SAN FRANCISCO CA 94107
Geoffrey Crouse	director	3130 GATEWAY DRIVE, P O BOX 5625, NORCROSS GA 30091-5625
Jason W. Myers	director, other: President, Oncology	C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301